E
Vaccinex, Inc. VCNX
$0.72 -$0.02-2.70% OTC PK
Recommendation
Prev Close
$0.74
Volume
1,964
Avg Vol (90D)
17,382
Market Cap
$1.98M
Dividend & Yield
--
52-Week Range
$0.2521 - $8.90
P/E (TTM)
--
EPS (TTM)
-$9.91
My Lists My Alerts
Access our Premium Ratings
Get Access
Rating
Reward
Risk
Rating Factors
Growth Index
Efficiency Index
Solvency Index
Total Return Index
Volatility Index
Dividend Index
Headlines
Vaccinex to Report Promising New Clinical Data Revealing Pepinemab's Unique Mechanism to Enhance Immunotherapy at Annual Meeting of American Association for Cancer Research (AACR)
4/21/2025 - Globe Newswire
Vaccinex Plans to Delist its Common Stock from The Nasdaq Stock Market
3/7/2025 - Globe Newswire
Vaccinex Faces Nasdaq Delisting Amid Financial Struggles; Shares Drop 62%
12/17/2024 - GuruFocus
Vaccinex receives delisting notice from Nasdaq, shares down over 49%
12/17/2024 - Seeking Alpha - Healthcare
Vaccinex receives delisting notification from Nasdaq
12/17/2024 - The Fly
Vaccinex Announces Receipt of Delisting Notification from Nasdaq
12/17/2024 - GuruFocus
Vaccinex Announces Receipt of Delisting Notification from Nasdaq
12/17/2024 - Globe Newswire
Vaccinex, Inc. (NASDAQ:VCNX) Shares Purchased by Point72 Asset Management L.P.
12/12/2024 - Ticker Report
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/18/2024 - GuruFocus
Vaccinex reports Q3 EPS ($2.83) vs. ($15.25) last year
11/18/2024 - The Fly
Vaccinex Reports Third Quarter 2024 Financial Results and Provides Corporate Update
11/18/2024 - Globe Newswire
ARMISTICE CAPITAL, LLC Acquires Shares in Vaccinex Inc
11/15/2024 - GuruFocus
Vaccinex provides update on ActivMAb platform
11/7/2024 - TipRanks Financial Blog
Vaccinex provides update on ActivMAb platform
11/7/2024 - The Fly
Vaccinex Provides Update on ActivMAb Platform: Multiple Project Deals and Presentation at SITC
11/7/2024 - Globe Newswire
Vaccinex to preset new biomarker data on HNSCC
11/5/2024 - The Fly
Vaccinex Reports Improved Immunity Correlating with Clinical Benefit of Pepinemab Combination Treatment at Society for Immunotherapy of Cancer's Annual Meeting
11/5/2024 - Globe Newswire
Vaccinex reports new findings from SIGNAL-AD Phase 1b/2 trial of pepinemab
10/31/2024 - TipRanks Financial Blog
Vaccinex reports new findings from SIGNAL-AD Phase 1b/2 trial of pepinemab
10/31/2024 - The Fly
Vaccinex Reports New Findings for SIGNAL-AD Phase 1b/2 Trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference in Madrid, Spain
10/31/2024 - Globe Newswire
Vaccinex announces it will present new data for Phase 1b/2 SIGNAL-AD study
10/24/2024 - The Fly
Vaccinex to Report Promising New Efficacy Data for SIGNAL-AD Phase 1b/2 trial of Pepinemab at Clinical Trials on Alzheimer's Disease (CTAD) Conference on October 31, 2024
10/24/2024 - Globe Newswire
Vaccinex files to sell 1.6M shares of common stock for holders
10/16/2024 - TipRanks Financial Blog
Vaccinex files to sell 1.6M shares of common stock for holders
10/16/2024 - The Fly
Income Statement
Total Revenue (TTM)
$601.00K
EBITDA (TTM)
-$18.64M
EBIT (TTM)
-$18.74M
Net Income (TTM)
-$18.63M
Balance Sheet
Total Assets (Q)
$2.60M
Total Debt (Q)
$25.00K
Total Liabilities (Q)
$5.08M
Book Value Per Share (Q)
-$1.55
Cash Flow
Cash from Operations (TTM)
-$16.19M
Cash from Investing (TTM)
-$22.00K
Cash from Financing (TTM)
$15.78M
Net Change in Cash (TTM)
-$428.00K
Filings
Filing Date
Tuesday, April 15, 2025
Period Date
Tuesday, December 31, 2024
Next Filing
Week of May 12 and 16 (est)
Price History
Loading...
Beta
2.62
7-Day Total Return
-17.24%
30-Day Total Return
-22.58%
60-Day Total Return
-34.55%
90-Day Total Return
-81.59%
Year to Date Total Return
-24.21%
1-Year Total Return
-85.00%
2-Year Total Return
-99.22%
3-Year Total Return
-99.71%
5-Year Total Return
-99.91%
52-week Low
Apr 10, 2025 - $0.2521
52-week High
Jul 30, 2024 - $8.90
Valuation
Market Cap
$1.98M - Nano Cap
Enterprise Value
$2.56M
Price/Sales (TTM)
3.97
Price/Book (Q)
-0.48
Dividends and Shares
Shares Outstanding
3.22M
Dividend Per Share (Most Recent)
--
Dividend Per Share (TTM)
--
Corporate Info
Website
www.vaccinex.com
Phone Number
585 271 2700
Address
1895 Mount Hope Avenue
Rochester, NY 14620
Country
United States
Year Founded
2001
Business Description
Sector
Health Care
Industry
Pharmaceuticals, Biotechnology and Life Sciences
Vaccinex, Inc., a clinical-stage biotechnology company, engages in the discovery and development of targeted biotherapeutics to treat cancer, neurodegenerative diseases, and autoimmune disorders... more
OTC PK 04/21/2025 3:59PM Eastern Quotes delayed